MARKET

IDYA

IDYA

Ideaya Biosciences
NASDAQ
36.99
-0.29
-0.78%
Pre Market: 37.05 +0.06 +0.16% 08:22 07/13 EDT
OPEN
37.01
PREV CLOSE
37.28
HIGH
37.42
LOW
35.92
VOLUME
1.87K
TURNOVER
0
52 WEEK HIGH
40.58
52 WEEK LOW
20.99
MARKET CAP
3.46B
P/E (TTM)
-23.1578
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IDYA last week (0706-0710)?
Weekly Report · 3h ago
IDEAYA Biosciences Chief Accounting Officer Andres Ruiz Briseno sells 9,550 shares for $382,131.94
PUBT · 3d ago
IDEAYA Biosciences (IDYA) Joins Russell Growth Benchmarks, Is The Stock Fully Priced?
Simply Wall St · 5d ago
IDEAYA Biosciences Price Target Cut to $48.00/Share From $53.00 by RBC Capital
Dow Jones · 5d ago
IDEAYA Biosciences Is Maintained at Outperform by RBC Capital
Dow Jones · 5d ago
RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48
Benzinga · 5d ago
Ideaya Biosciences price target lowered to $63 from $65 at Truist
TipRanks · 5d ago
IDEAYA Biosciences Is Maintained at Buy by Truist Securities
Dow Jones · 5d ago
More
About IDYA
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.

Webull offers Ideaya Biosciences Inc stock information, including NASDAQ: IDYA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDYA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IDYA stock methods without spending real money on the virtual paper trading platform.